中信证券股份有限公司 关于杭州安杰思医学科技股份有限公司 2025 年半年度持续督导跟踪报告 1 中信证券股份有限公司（以下简称"中信证券"或"保荐人"）作为杭州安 杰思医学科技股份有限公司（以下简称"安杰思"或"公司"或"上市公司"） 首次公开发行股票并在科创板上市的保荐人，根据《证券发行上市保荐业务管理 办法》《上海证券交易所科创板股票上市规则》等相关规定，中信证券履行持续 督导职责，并出具本持续督导年度跟踪报告。 一、持续督导工作概述 1、保荐人制定了持续督导工作制度，制定了相应的工作计划，明确了现场 检查的工作要求。 2、保荐人已与公司签订保荐协议，该协议已明确了双方在持续督导期间的 权利义务，并报上海证券交易所备案。 3、本持续督导期间，保荐人通过与公司的日常沟通、现场回访等方式开展 持续督导工作，并于 2025 年 7 月 14 日对公司进行了现场检查。 4、本持续督导期间，保荐人根据相关法规和规范性文件的要求履行持续督 导职责，具体内容包括： （1）查阅公司章程、三会议事规则等公司治理制度、三会会议材料； （2）查阅公司财务管理、会计核算和内部审计等内部控制制度； （3）查阅公司与控股股东、实际 ...

Company Overview - Anjess Medical Technology Co., Ltd. is located in Hangzhou, Zhejiang Province, and was established on December 6, 2010. The company went public on May 19, 2023. Its main business involves the research, development, production, and sales of endoscopic minimally invasive diagnostic and therapeutic devices [1][2]. Financial Performance - For the first half of 2025, Anjess achieved operating revenue of 302 million yuan, representing a year-on-year growth of 14.56%. The net profit attributable to the parent company was 126 million yuan, with a year-on-year increase of 1.26% [2]. - Since its A-share listing, Anjess has distributed a total of 239 million yuan in dividends [3]. Stock Performance - As of August 22, Anjess's stock price was 82.37 yuan per share, with a market capitalization of 6.67 billion yuan. The stock has increased by 41.25% year-to-date, but has seen a slight decline of 0.19% over the last five trading days and 0.16% over the last twenty days [1]. - The stock's trading volume on August 22 was 26.16 million yuan, with a turnover rate of 0.76%. The net outflow of main funds was 3.83 million yuan, with large orders accounting for 14.80% of purchases and 29.44% of sales [1]. Shareholder Information - As of August 20, the number of shareholders for Anjess was 5,293, a decrease of 1.34% from the previous period. The average number of circulating shares per person increased by 1.36% to 7,824 shares [2]. - As of June 30, 2025, Hong Kong Central Clearing Limited has exited the list of the top ten circulating shareholders [3]. Business Segmentation - Anjess's main business revenue composition is as follows: GI category 62.74%, EMR/ESD category 23.26%, ERCP category 11.04%, instruments category 2.21%, and others 0.74% [1].

Group 1 - The medical device sector has gained significant attention, with 125 out of 131 companies in the A-share market experiencing stock price increases in the past month, and Sino Medical Science Technology Co., Ltd. achieving a remarkable stock price increase of 207.59% [1] - Institutional investors are actively researching the medical device industry, indicating a reassessment of growth potential in this sector [1] - The Chinese government has introduced supportive policies to accelerate the high-quality development of the medical device industry, aiming to transition from a major pharmaceutical country to a strong one [1] Group 2 - In July, the National Medical Products Administration released measures to support innovation in high-end medical devices, including medical robots and AI medical devices, highlighting the government's focus on high-end innovation [2] - The high-end medical device market in China is projected to grow rapidly, with an estimated market size of 2.8 trillion yuan by 2030, driven by technological advancements and domestic replacements [2] - The push for high-end innovation is expected to break the "low-end lock-in" in the medical device industry, enhancing the overall value and international competitiveness of the sector [2] Group 3 - Companies like Maide Medical Industrial Equipment Co., Ltd. are expanding their overseas channels through exhibitions and customer visits, with overseas orders expected to exceed 60 million yuan by the end of 2024 [3] - Anjies Medical Technology Co., Ltd. is deepening its global layout through localized operations and overseas production bases, successfully selling products to over 60 countries [3] - The global demand for medical devices is increasing, particularly in emerging markets, providing significant opportunities for Chinese medical device companies to expand internationally [3]

Group 1 - The core viewpoint of the news is that Anjiasi's stock price has increased by 6.07% to 87.93 yuan, with a rolling PE ratio of 24.14, marking a new low in 318 days, and a total market capitalization of 7.12 billion yuan [1] - Anjiasi ranks 48th in the medical device industry, which has an average PE ratio of 59.32 and a median of 39.97 [1] - As of July 31, 2025, Anjiasi has 5,365 shareholders, an increase of 202 from the previous count, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Group 2 - Anjiasi specializes in the research, production, and sales of minimally invasive diagnostic and therapeutic instruments, with main products including GI, EMR/ESD, and ERCP diagnostic series [1] - The company has received multiple government honors, including the title of "Zhejiang Province Export Brand" and the "Quality Award" from the Linping District Government [1] - In the latest semi-annual report for 2025, Anjiasi achieved an operating income of 302 million yuan, a year-on-year increase of 14.56%, and a net profit of 126 million yuan, with a gross profit margin of 70.21% [1]

证券之星消息，8月20日医疗器械板块较上一交易日上涨0.06%，济民健康领涨。当日上证指数报收于 3766.21，上涨1.04%。深证成指报收于11926.74，上涨0.89%。医疗器械板块个股涨跌见下表： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。 | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 603222 | 济民健康 | 11.86 | 10.02% | 164.39万 | | 18.28亿 | | 300642 | 透景生命 | 24.81 | 7.45% | 35.17万 | | 8.65 Z | | 688581 | 安杰思 | 87.93 | 6.07% | 2.57万 | | 2.20亿 | | 301093 | 华兰股份 | 34.04 | 4.58% | 13.19万 | | 4.45亿 | | 600645 | 中源协和 | 29.66 | 3.27% | 23.37万 | | ...

Company Overview - Anjias Medical Technology Co., Ltd. specializes in the research, production, and sales of minimally invasive diagnostic and therapeutic instruments, particularly in the endoscopy sector [1] - The company's main products include GI series, EMR/ESD series, ERCP diagnostic series, and therapeutic instruments [1] - Anjias has received several government honors, including the "Zhejiang Province Export Brand" title and the "Quality Award" from the Linping District Government [1] Financial Performance - For the first half of 2025, the company reported a revenue of 302 million yuan, representing a year-on-year increase of 14.56% [1] - The net profit for the same period was 126 million yuan, with a year-on-year growth of 1.26% [1] - The sales gross margin stood at 70.21% [1] Market Position - As of the latest data, Anjias's rolling price-to-earnings (PE) ratio is 22.76, while the industry average PE ratio is 59.49 [2] - The company's total market capitalization is 6.713 billion yuan [1] - Anjias ranks 48th in the medical device industry based on PE ratio, with the industry median at 40.19 [1][2] Shareholding Structure - As of the 2025 semi-annual report, a total of 10 institutions hold shares in Anjias, including 5 other entities, 4 funds, and 1 brokerage, with a total holding of 17.6384 million shares valued at 1.143 billion yuan [1]

Core Viewpoint - Recent institutional research activities indicate strong interest in specific industries and companies within the capital market, reflecting market expectations and potential future trends [1] Group 1: Institutional Research Activities - Over 200 listed companies received institutional research from August 11 to August 17, indicating significant interest from the capital market [1] - Notable companies receiving attention include Nanwei Medical, Anjiasi, and Jinchengzi, with Nanwei Medical hosting 184 institutions on August 12 [2][3] Group 2: Company Performance and Insights - Nanwei Medical reported a revenue of 1.565 billion yuan for the first half of 2025, a year-on-year increase of 17.36%, and a net profit of 363 million yuan, up 17.04% [3][4] - Anjiasi achieved a revenue of 302 million yuan in the first half of 2025, reflecting a growth of 14.56%, with a net profit of 126 million yuan, also up 1.26% [4] - Jinchengzi's main business focuses on laser processing control systems, with recent inquiries from institutional investors regarding acquisition strategies [5] Group 3: Industry Trends and Future Outlook - The medical, technology, and consumer electronics sectors were highlighted as key areas of focus for institutional research during the specified period [6] - The medical industry is expected to experience positive changes, with opportunities arising from advancements in artificial intelligence and surgical robotics, projected to exceed 70 billion yuan by 2030 [6] - Policy shifts supporting innovation in the medical device sector are anticipated to lead to valuation and performance recovery for many companies, with a focus on domestic procurement optimization and export growth [6]

Group 1 - In the past five trading days, a total of 98 companies were investigated by institutions, with securities companies participating in 93.88% of the activities [1] - Among the companies, Nanwei Medical received the most attention with 184 institutions participating in the investigation, followed by Anjisi with 179 institutions, and Jinchengzi with 166 institutions [1] - A total of 46 companies were investigated by more than 20 institutions, and 17 of these companies experienced net capital inflow in the past five days, with Dahua Co., Ltd. seeing the highest net inflow of 430 million yuan [1] Group 2 - In terms of market performance, 36 stocks among those investigated rose in the past five days, with Hai Neng Technology leading with an increase of 88.23%, followed by Yishitong and Jinchengzi with increases of 37.41% and 23.42% respectively [2] - Among the stocks investigated, 38 have released semi-annual reports, with Zhenlei Technology and Shengnuo Bio recording the highest net profit growth rates of 1006.99% and 308.29% respectively [2] - Microchip Biotech is expected to have the highest median net profit growth rate of 173.00%, with an estimated net profit of 30 million yuan [2] Group 3 - The list of companies investigated includes Nanwei Medical, Anjisi, Jinchengzi, and others, with varying numbers of institutional investigations and stock price changes [3][4][5][6] - Companies like Ganyuan Food and Shuanghui Development were investigated twice, indicating a higher frequency of institutional interest [3][4] - The performance of stocks varied, with some experiencing significant gains while others faced declines, reflecting the mixed sentiment among investors [2][3][4][5][6]

Group 1 - A-shares entered a concentrated disclosure period for mid-term reports, with public fund research enthusiasm rising significantly, as 139 public fund institutions participated in A-share research activities last week, covering 66 stocks across 20 Shenwan primary industries, with a total of 729 research instances, representing a week-on-week increase of 46.39% [1][2] - The leading stock in the beauty and personal care sector, Baiya Co., was the most researched, with 53 instances of public fund research, attracting over 30% of public fund institutions including Bosera Fund, Harvest Fund, and China Merchants Fund [1][2] - The pharmaceutical and biological sector received high attention from public fund institutions, with three stocks making the top ten in research instances: Nanwei Medical (46 times), Anjiasi (32 times), and Anke Biological (32 times) [1][2] Group 2 - The computer industry also saw significant interest, with two stocks in the top ten: Desai Xiwai (46 times) and Jinchengzi (45 times) [1][2] - The pharmaceutical and biological sector was the most favored by public fund research, with a total of 10 stocks receiving attention, accumulating 151 research instances, leading other industries in both the number of researched stocks and research instances [2] - Other industries such as electronics, electric equipment, basic chemicals, and beauty care also received attention, with each being researched at least 50 times, ranking in the top ten [3] Group 3 - Among institutions, Penghua Fund led with 20 research instances covering 19 stocks across 11 industries, with a relatively high proportion in electric equipment, electronics, and basic chemicals [3] - Guotai Fund and Southern Fund both ranked second with 14 research instances each, focusing on different sectors, with Guotai Fund emphasizing pharmaceutical and biological stocks, while Southern Fund covered a broader range including electronics, computers, electric equipment, and basic chemicals [3]

Group 1 - A total of 23 companies were investigated by well-known institutions from August 11 to August 17, with the pharmaceutical and biotechnology sector leading in interest [1][2] - Nanwei Medical received the highest number of institutional investigations, totaling 183, followed by Anjisi with 180 and Jinchengzi with 166 [1][2] - Other notable companies investigated include Xinqianglian (163), Desai Xiwai (160), and Zhenlei Technology (74) [1][2] Group 2 - The investigation period for Nanwei Medical was on August 12, while Anjisi and Jinchengzi were investigated on August 12 and August 13, respectively [1][2] - The sectors represented among the investigated companies include medical biology, computer, electrical equipment, electronics, food and beverage, and basic chemicals [1][2][3] - Notable investment firms involved in the investigations include Gao Yi Asset, Chongyang, and Shibei [1][2][3]